Back

루멘스바이오스 KOSDAQ

038060

Suggest a tag

Watch

Notes Naver Finance

Upcoming shareholder meeting

Extraordinary

2026.10.29 DART

Meeting date 2026.11.09 09:00 Location 경기도 용인시 기흥구 하갈로 86번길 51 3층 본사 대회의실

• 제1호 의안: 자본감소(무상감자) 승인의 건
• 제2호 의안: 감사 선임의 건

Meeting voting results

Previous meeting results

Financial indicators

Market cap

202 × 100M KRW

PBR

0.17

PER

ROE

-6.12%

Dividend yield

Debt-to-equity ratio

47.4%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2026 Semiannual report (2026-06-30)

Controlling shareholders total

21.97%

Minority shareholders (excl. related parties)

68.20%

Large outside holders (1%+)

9.83% (4 people)

Treasury shares

0.00%

Total shareholders

13,177 people

Annual earnings Trend

Financial statements

Consolidated · includes subsidiaries

루멘스바이오스 — Annual Consolidated Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	6,141.6 × 100M KRW	5,244.8 × 100M KRW	4,256.2 × 100M KRW	4,028.4 × 100M KRW	3,615.7 × 100M KRW	3,258.3 × 100M KRW	3,235.9 × 100M KRW	2,052.5 × 100M KRW	1,723.4 × 100M KRW	1,663 × 100M KRW	1,712.4 × 100M KRW	1,742.3 × 100M KRW	1,755.4 × 100M KRW
Operating profit	525 × 100M KRW	200.8 × 100M KRW	61.4 × 100M KRW	52.4 × 100M KRW	-92.1 × 100M KRW	-203.8 × 100M KRW	-392.2 × 100M KRW	-11.8 × 100M KRW	7.9 × 100M KRW	11.9 × 100M KRW	27.4 × 100M KRW	-16.2 × 100M KRW	-50.3 × 100M KRW
Net income	324.2 × 100M KRW	117.4 × 100M KRW	-79.3 × 100M KRW	-62.3 × 100M KRW	11.7 × 100M KRW	-314.8 × 100M KRW	-611.1 × 100M KRW	-283.1 × 100M KRW	-294.3 × 100M KRW	158.9 × 100M KRW	40.1 × 100M KRW	88.4 × 100M KRW	-66.5 × 100M KRW
Operating margin	8.55%	3.83%	1.44%	1.30%	-2.55%	-6.26%	-12.12%	-0.58%	0.46%	0.72%	1.60%	-0.93%	-2.86%
Balance sheet
Total assets	3,342.8 × 100M KRW	3,524.6 × 100M KRW	3,400 × 100M KRW	3,499 × 100M KRW	3,455.1 × 100M KRW	3,328.7 × 100M KRW	2,784.5 × 100M KRW	2,386.4 × 100M KRW	1,826.8 × 100M KRW	1,376 × 100M KRW	1,464.6 × 100M KRW	1,683.2 × 100M KRW	1,561.1 × 100M KRW
Total liabilities	1,269.6 × 100M KRW	1,231.4 × 100M KRW	1,207 × 100M KRW	1,360.4 × 100M KRW	1,234.4 × 100M KRW	1,414.4 × 100M KRW	1,478.9 × 100M KRW	1,411.6 × 100M KRW	1,088.9 × 100M KRW	439.2 × 100M KRW	486.5 × 100M KRW	568.8 × 100M KRW	501.7 × 100M KRW
Total equity	2,073.2 × 100M KRW	2,293.2 × 100M KRW	2,192.9 × 100M KRW	2,138.6 × 100M KRW	2,220.7 × 100M KRW	1,914.3 × 100M KRW	1,305.6 × 100M KRW	974.8 × 100M KRW	737.8 × 100M KRW	936.8 × 100M KRW	978 × 100M KRW	1,114.4 × 100M KRW	1,059.4 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	43.3 × 100M KRW	149.5 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-79.8 × 100M KRW	-17.5 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-30.1 × 100M KRW	-72.7 × 100M KRW
Investment indicators
ROE	15.64%	5.12%	-3.62%	-2.91%	0.52%	-16.45%	-46.81%	-29.04%	-39.88%	16.96%	4.10%	7.93%	-6.28%
Debt-to-equity ratio	61.24%	53.70%	55.04%	63.61%	55.58%	73.89%	113.28%	144.81%	147.59%	46.89%	49.74%	51.04%	47.36%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	KRW 25	-	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	2,091.7 × 100M KRW	-	-	1,787 × 100M KRW	-	-	1,372 × 100M KRW	-	-	1,307.8 × 100M KRW	1,237.3 × 100M KRW
Non-current assets	-	-	1,308.3 × 100M KRW	-	-	1,541.7 × 100M KRW	-	-	149.3 × 100M KRW	-	-	375.4 × 100M KRW	323.8 × 100M KRW
Current liabilities	-	-	1,019.9 × 100M KRW	-	-	1,212.1 × 100M KRW	-	-	1,072.9 × 100M KRW	-	-	467.5 × 100M KRW	403.3 × 100M KRW
Non-current liabilities	-	-	187.2 × 100M KRW	-	-	202.4 × 100M KRW	-	-	16 × 100M KRW	-	-	101.3 × 100M KRW	98.5 × 100M KRW
Equity attributable to owners	-	-	-	-	-	-	-	-	-	-	-	1,114.4 × 100M KRW	1,059.4 × 100M KRW
Share capital	-	-	-	-	-	236.4 × 100M KRW	-	-	240.5 × 100M KRW	-	-	240.5 × 100M KRW	240.5 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	1,114.7 × 100M KRW	1,114.7 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-84.5 × 100M KRW	-84.5 × 100M KRW
Accumulated other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	20.5 × 100M KRW	32 × 100M KRW
Retained earnings	-	-	-	-	-	614.7 × 100M KRW	-	-	-471.6 × 100M KRW	-	-	-176.8 × 100M KRW	-243.3 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

루멘스바이오스 — Quarterly Consolidated Financial statements
Item	26/3	26/6
Income statement
Revenue	382.4 × 100M KRW	346.8 × 100M KRW
Operating profit	9.1 × 100M KRW	-18 × 100M KRW
Net income	23.2 × 100M KRW	-8.2 × 100M KRW
Operating margin	2.39%	-5.19%
Balance sheet
Total assets	1,530 × 100M KRW	1,545.4 × 100M KRW
Total liabilities	433.3 × 100M KRW	447.4 × 100M KRW
Total equity	1,096.7 × 100M KRW	1,098 × 100M KRW
Cash flow statement
Operating cash flow	-27.7 × 100M KRW	51 × 100M KRW
Investing cash flow	-8.5 × 100M KRW	2.4 × 100M KRW
Financing cash flow	-1.9 × 100M KRW	-1.1 × 100M KRW
Investment indicators
Debt-to-equity ratio	39.51%	40.75%
EPS	-	-
Detailed accounts
Current assets	1,197.7 × 100M KRW	1,210.5 × 100M KRW
Non-current assets	332.3 × 100M KRW	334.9 × 100M KRW
Current liabilities	319.6 × 100M KRW	341.7 × 100M KRW
Non-current liabilities	113.7 × 100M KRW	105.7 × 100M KRW
Equity attributable to owners	1,096.7 × 100M KRW	1,098 × 100M KRW
Share capital	240.5 × 100M KRW	240.5 × 100M KRW
Capital surplus	1,114.7 × 100M KRW	1,114.7 × 100M KRW
Other equity	-84.5 × 100M KRW	-84.5 × 100M KRW
Accumulated other comprehensive income	46.1 × 100M KRW	55.5 × 100M KRW
Retained earnings	-220.1 × 100M KRW	-228.3 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Separate · this company only

루멘스바이오스 — Annual Separate Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	6,032.8 × 100M KRW	5,004.3 × 100M KRW	3,988.8 × 100M KRW	3,494.1 × 100M KRW	2,933.9 × 100M KRW	1,554.2 × 100M KRW	1,407 × 100M KRW	1,359.3 × 100M KRW	1,297.6 × 100M KRW	1,087.1 × 100M KRW	997.7 × 100M KRW	835.3 × 100M KRW	879.6 × 100M KRW
Operating profit	508.1 × 100M KRW	179.2 × 100M KRW	15.8 × 100M KRW	12.6 × 100M KRW	-146.8 × 100M KRW	-213.9 × 100M KRW	-400.8 × 100M KRW	-26.8 × 100M KRW	71.6 × 100M KRW	39.6 × 100M KRW	16.8 × 100M KRW	-10 × 100M KRW	-10.8 × 100M KRW
Net income	322.1 × 100M KRW	97.1 × 100M KRW	-106.1 × 100M KRW	-68 × 100M KRW	-148.5 × 100M KRW	-254.9 × 100M KRW	-555.6 × 100M KRW	-110.6 × 100M KRW	-250.4 × 100M KRW	109.4 × 100M KRW	28.9 × 100M KRW	71.5 × 100M KRW	7.5 × 100M KRW
Operating margin	8.42%	3.58%	0.40%	0.36%	-5.00%	-13.76%	-28.49%	-1.98%	5.52%	3.64%	1.68%	-1.20%	-1.22%
Balance sheet
Total assets	3,240.9 × 100M KRW	3,294 × 100M KRW	3,280.5 × 100M KRW	3,213.9 × 100M KRW	2,884.9 × 100M KRW	2,600.7 × 100M KRW	1,936.7 × 100M KRW	1,720.4 × 100M KRW	1,659.8 × 100M KRW	1,270.8 × 100M KRW	1,277.1 × 100M KRW	1,482.4 × 100M KRW	1,457.4 × 100M KRW
Total liabilities	1,205.6 × 100M KRW	1,077.7 × 100M KRW	1,178 × 100M KRW	1,161.3 × 100M KRW	993.7 × 100M KRW	952.2 × 100M KRW	853 × 100M KRW	765.4 × 100M KRW	927.1 × 100M KRW	388.6 × 100M KRW	366.4 × 100M KRW	477 × 100M KRW	444.4 × 100M KRW
Total equity	2,035.2 × 100M KRW	2,216.3 × 100M KRW	2,102.5 × 100M KRW	2,052.6 × 100M KRW	1,891.2 × 100M KRW	1,648.5 × 100M KRW	1,083.7 × 100M KRW	955 × 100M KRW	732.7 × 100M KRW	882.2 × 100M KRW	910.7 × 100M KRW	1,005.4 × 100M KRW	1,012.9 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	35.1 × 100M KRW	32.2 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	-99.3 × 100M KRW	63.2 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	-5.5 × 100M KRW	-6.4 × 100M KRW
Investment indicators
ROE	15.83%	4.38%	-5.05%	-3.32%	-7.85%	-15.46%	-51.27%	-11.58%	-34.18%	12.40%	3.17%	7.11%	0.74%
Debt-to-equity ratio	59.24%	48.63%	56.03%	56.58%	52.54%	57.76%	78.71%	80.14%	126.52%	44.05%	40.24%	47.44%	43.88%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	KRW 25	-	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	2,106.4 × 100M KRW	-	-	1,327.2 × 100M KRW	-	-	1,033.9 × 100M KRW	-	-	900.8 × 100M KRW	945.8 × 100M KRW
Non-current assets	-	-	1,174.2 × 100M KRW	-	-	1,273.5 × 100M KRW	-	-	320.3 × 100M KRW	-	-	581.6 × 100M KRW	511.6 × 100M KRW
Current liabilities	-	-	954.7 × 100M KRW	-	-	829.2 × 100M KRW	-	-	914.3 × 100M KRW	-	-	383.5 × 100M KRW	349.9 × 100M KRW
Non-current liabilities	-	-	223.3 × 100M KRW	-	-	123 × 100M KRW	-	-	12.7 × 100M KRW	-	-	93.4 × 100M KRW	94.5 × 100M KRW
Share capital	-	-	236.4 × 100M KRW	-	-	236.4 × 100M KRW	-	-	240.5 × 100M KRW	-	-	240.5 × 100M KRW	240.5 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	1,114.7 × 100M KRW	1,114.7 × 100M KRW
Other equity	-	-	-	-	-	-	-	-	-	-	-	-12.8 × 100M KRW	-12.8 × 100M KRW
Accumulated other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	-43.8 × 100M KRW	-43.8 × 100M KRW
Retained earnings	-	-	846.6 × 100M KRW	-	-	408.2 × 100M KRW	-	-	-510.4 × 100M KRW	-	-	-293.2 × 100M KRW	-285.7 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

루멘스바이오스 — Quarterly Separate Financial statements
Item	26/3	26/6
Income statement
Revenue	199 × 100M KRW	150.4 × 100M KRW
Operating profit	-2.7 × 100M KRW	-17.9 × 100M KRW
Net income	8.9 × 100M KRW	-2.8 × 100M KRW
Operating margin	-1.37%	-11.93%
Balance sheet
Total assets	1,391.2 × 100M KRW	1,381.9 × 100M KRW
Total liabilities	369.3 × 100M KRW	362.8 × 100M KRW
Total equity	1,021.8 × 100M KRW	1,019.1 × 100M KRW
Cash flow statement
Operating cash flow	-9 × 100M KRW	19.6 × 100M KRW
Investing cash flow	-7.8 × 100M KRW	2.5 × 100M KRW
Financing cash flow	-1.7 × 100M KRW	-9,604 × 10,000 KRW
Investment indicators
Debt-to-equity ratio	36.14%	35.60%
EPS	-	-
Detailed accounts
Current assets	878.6 × 100M KRW	865.8 × 100M KRW
Non-current assets	512.5 × 100M KRW	516.1 × 100M KRW
Current liabilities	259.6 × 100M KRW	261 × 100M KRW
Non-current liabilities	109.7 × 100M KRW	101.8 × 100M KRW
Share capital	240.5 × 100M KRW	240.5 × 100M KRW
Capital surplus	1,114.7 × 100M KRW	1,114.7 × 100M KRW
Other equity	-12.8 × 100M KRW	-12.8 × 100M KRW
Accumulated other comprehensive income	-43.8 × 100M KRW	-43.8 × 100M KRW
Retained earnings	-276.8 × 100M KRW	-279.6 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Legacy summaries and estimates; may include data with unverified accounting scope.

루멘스바이오스 — Annual Legacy summary & estimates Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023 Consolidated	2024 Consolidated	2025 Consolidated
Income statement
Revenue	6,141.6 × 100M KRW	5,244.8 × 100M KRW	4,256.2 × 100M KRW	4,028.4 × 100M KRW	3,615.7 × 100M KRW	3,258.3 × 100M KRW	3,235.9 × 100M KRW	2,052.5 × 100M KRW	1,723.4 × 100M KRW	1,663 × 100M KRW	1,712.4 × 100M KRW	1,742.3 × 100M KRW	1,755.4 × 100M KRW
Operating profit	525 × 100M KRW	200.8 × 100M KRW	61.4 × 100M KRW	52.4 × 100M KRW	-92.1 × 100M KRW	-203.8 × 100M KRW	-392.2 × 100M KRW	-11.8 × 100M KRW	7.9 × 100M KRW	11.9 × 100M KRW	27.4 × 100M KRW	-16.2 × 100M KRW	-50.3 × 100M KRW
Net income	324.2 × 100M KRW	117.4 × 100M KRW	-79.3 × 100M KRW	-62.3 × 100M KRW	11.7 × 100M KRW	-314.8 × 100M KRW	-	-	-	158.9 × 100M KRW	40.1 × 100M KRW	88.4 × 100M KRW	-66.5 × 100M KRW
Operating margin	8.55%	3.83%	1.44%	1.30%	-2.55%	-6.26%	-12.12%	-0.58%	0.46%	0.72%	1.60%	-0.93%	-2.86%
Balance sheet
Total assets	-	-	-	-	-	-	-	-	-	-	1,464.6 × 100M KRW	1,683.2 × 100M KRW	1,561.1 × 100M KRW
Total liabilities	1,269.6 × 100M KRW	1,231.4 × 100M KRW	1,207 × 100M KRW	1,360.4 × 100M KRW	1,234.4 × 100M KRW	1,414.4 × 100M KRW	1,478.9 × 100M KRW	1,411.6 × 100M KRW	1,088.9 × 100M KRW	439.2 × 100M KRW	486.5 × 100M KRW	568.8 × 100M KRW	501.7 × 100M KRW
Total equity	2,073.2 × 100M KRW	2,293.2 × 100M KRW	2,192.9 × 100M KRW	2,138.6 × 100M KRW	2,220.7 × 100M KRW	1,914.3 × 100M KRW	1,305.6 × 100M KRW	974.8 × 100M KRW	737.8 × 100M KRW	936.8 × 100M KRW	978 × 100M KRW	1,114.4 × 100M KRW	1,059.4 × 100M KRW
Investment indicators
ROE	15.64%	5.12%	-3.62%	-2.91%	0.52%	-16.45%	-	-	-	16.96%	4.10%	7.93%	-6.28%
Debt-to-equity ratio	61.24%	53.70%	55.04%	63.61%	55.58%	73.89%	113.28%	144.81%	147.59%	46.89%	49.74%	51.04%	47.36%
Separate total assets	-	-	-	-	-	-	-	-	-	-	1,277.1 × 100M KRW	1,482.4 × 100M KRW	1,457.4 × 100M KRW
EPS	-	-	-	-	-	-	-	-	-	KRW 330	KRW 83	KRW 184	KRW -138
PER	-	-	-	-	-	-	-	-	-	3.09×	15.53×	5.81×	-4.43×
PBR	-	-	-	-	-	-	-	-	-	0.51	0.62	0.46	0.28
Dividend per share	-	KRW 25	-	-	-	-	-	-	-	-	-	-	-

루멘스바이오스 — Quarterly Legacy summary & estimates Financial statements
Item	24/3	24/6	24/9	24/12 Consolidated	25/3	25/6	25/9	25/12 Consolidated	26/3	26/6
Income statement
Revenue	391.9 × 100M KRW	416.8 × 100M KRW	479.7 × 100M KRW	-	479 × 100M KRW	367.2 × 100M KRW	444 × 100M KRW	-	382.4 × 100M KRW	346.8 × 100M KRW
Operating profit	12.5 × 100M KRW	8.8 × 100M KRW	8.2 × 100M KRW	-	8.5 × 100M KRW	-20.6 × 100M KRW	-19.4 × 100M KRW	-	9.1 × 100M KRW	-18 × 100M KRW
Net income	31.6 × 100M KRW	13.5 × 100M KRW	5 × 100M KRW	-	7 × 100M KRW	-50.8 × 100M KRW	-1.4 × 100M KRW	-	23.2 × 100M KRW	-8.2 × 100M KRW
Operating margin	3.19%	2.12%	1.72%	-	1.76%	-5.60%	-4.37%	-	2.39%	-5.19%
Balance sheet
Total assets	1,609.1 × 100M KRW	1,682.2 × 100M KRW	1,591.4 × 100M KRW	1,683.2 × 100M KRW	1,782.9 × 100M KRW	1,534.8 × 100M KRW	1,528.8 × 100M KRW	1,561.1 × 100M KRW	1,530 × 100M KRW	1,545.4 × 100M KRW
Total liabilities	597.6 × 100M KRW	626.7 × 100M KRW	530.7 × 100M KRW	568.8 × 100M KRW	658.3 × 100M KRW	471.2 × 100M KRW	457.2 × 100M KRW	501.7 × 100M KRW	433.3 × 100M KRW	447.4 × 100M KRW
Total equity	1,011.5 × 100M KRW	1,055.5 × 100M KRW	1,060.7 × 100M KRW	1,114.4 × 100M KRW	1,124.6 × 100M KRW	1,063.6 × 100M KRW	1,071.6 × 100M KRW	1,059.4 × 100M KRW	1,096.7 × 100M KRW	1,098 × 100M KRW
Investment indicators
Debt-to-equity ratio	59.08%	59.37%	50.04%	51.04%	58.53%	44.30%	42.67%	47.36%	39.51%	40.75%
EPS	-	-	-	-	-	-	-	-	-	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Property holdings

Total book value

28 × 100M KRW

Total assessed land value

Ratio to market cap

13.9%

Land

0 records

Buildings

3 records

Category	Location	Use	Area	Book value	Assessed land value
Building Unverified	Location unknown	LED 사업부 생산설비	-	25 × 100M KRW	-
Building Unverified	Location unknown	전장사업부 생산설비	-	3 × 100M KRW	-
Building Unverified	Location unknown	LGP 사업부 생산설비	-	-	-

Ownership structure

Is a listed company shown as unlisted?

Corporate shareholders

Corporate and institutional holders identified in collected disclosures. This is not a complete shareholder register. Reporting-group holdings may overlap with individual holdings.

Business report analysis

Analysis date 2026.04.26 23:23 | Based on 2025 Annual report

Unverified Original business report

사업 개요

주식회사 루멘스는 LED 및 광학부품, 자동차 전장 관련 제품을 설계·제조·판매하는 회사입니다. 1996년 설립되었으며, 주력 산업은 LED 사업, LGP(도광판) 사업, 자동차 전장사업입니다.

주요 매출원

LED사업부: 약 1,047억원 (2025년 매출액 104,718백만원)
전장사업부: 약 400억원 (2025년 매출액 40,014백만원)
LGP사업부: 약 307억원 (2025년 매출액 30,705백만원)
금융업: 약 1억원 (2025년 매출액 101백만원)
연결 기준 총매출액은 약 1,755억원이며, 전년 약 1,742억원 대비 소폭 증가했습니다.

원가 구조 / 비용 특성

영업이익은 2025년 약 -50억원으로, 2024년 약 -16억원에서 적자 폭이 확대되었습니다.
LGP사업부는 생산공정 변화(Roll Stamping 공정 도입) 및 베트남 현지법인 생산 집중을 통해 원가구조 개선을 진행 중이라고 기재되어 있습니다.

자회사

곤산류명광전유한공사: LED PKG 사업
Lumens VINA: LED 모듈 사업

차입 구조

해당사항 없음.

Employees

92 people

Subsidiaries

2 items

Material subsequent events

해당사항 없음.

Articles of incorporation analysis

Analysis date 2026.06.19 09:25 | Last amended 2025.01.03

Unverified Original articles of incorporation

주주친화

동등배당: 배당 기준일 현재 발행 또는 전환된 동종 주식에 대해 발행일과 관계없이 동등하게 배당한다고 규정 (제10조의4)

주주비친화

집중투표제 명시적 배제: 2인 이상의 이사를 선임하는 경우 상법 제382조의2의 집중투표제를 적용하지 않는다고 명시해 소수주주의 이사 선임 가능성을 제한 (제30조⑤)
이사회 결의만으로 500억원 전환사채 제3자 배정: 경영상 목적 등 사유로 주주 외의 자에게 전환사채를 발행할 수 있어 경영권 분쟁 시 우호지분 확보 수단이 될 수 있음 (제14조①)
이사회 결의만으로 500억원 신주인수권부사채 제3자 배정: 주주 외의 자에게 신주인수권부사채를 발행할 수 있어 기존 주주 지분 희석 위험이 있음 (제15조①)
이사 책임감경 조항: 이사의 책임을 최근 1년 보수액의 6배, 사외이사는 3배 초과분에 대해 면제할 수 있어 주주대표소송의 실효성을 약화시킬 수 있음 (제40조의2)
이사 임기 3년 고정: 상법상 최장 수준의 3년 임기를 정해 이사회 교체 속도를 늦출 수 있음 (제31조①)

기타 주목 조항

보궐이사 임기: 보궐선임된 이사 및 감사의 임기는 전임자의 잔여기간으로 제한 (제32조②)
감사 1명 이상: 감사위원회가 아닌 감사를 1명 이상 두는 구조 (제29조②)
이사·감사 보수와 퇴직금: 보수한도는 주주총회 결의로 정하고, 퇴직금은 주주총회 결의를 거친 임원퇴직금지급규정에 따름 (제40조)

Board of directors

Number of directors

At least 3 people

Director term

3 years (Fixed)

Remaining term for replacements

Staggered board

None

Cumulative voting

Separate chair and CEO

Gender diversity requirement

Director liability limitation

Exemption above 6.0×

Auditors

Number of auditors

At least 1 person

Auditor term

3 years (Fixed)

Shareholder meetings and dividends

Meeting notice period

14 days

Written voting

Electronic voting

Dividend record date

이사회 결의로 정하는 기준일

Third-party allotment limit by board resolution alone

Convertible bonds (CB)

500 × 100M KRW

Bonds with warrants (BW)

500 × 100M KRW

Compensation basis

Director: 이사 보수한도는 주주총회의 결의로 정한다.
Auditors: 감사 보수한도는 주주총회의 결의로 정한다.
Retirement payments: 이사와 감사의 퇴직금은 주주총회 결의를 거친 임원퇴직금지급규정에 의한다.

Executive compensation

Based on 2025 Annual report

Total compensation

2 × 100M KRW

Executives

5 people

Average per executive

4,700 × 10,000 KRW

Total dividends

Compensation / dividends

No dividend

Controlling shareholders

Name	Relationship	Age	Ownership
디티씨	Controlling shareholder	-	21.97%
노청희	Related party	Age 55	0.33%

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
디티씨	21.97%	10,566,637	0.00%	주식 양수도 계약 체결	일반	2026-08-13
넥스턴앤롤코리아	21.97%	10,566,637	+21.97%	주식 양수도 계약 [보통주(구주)]	일반	2026-08-12
디티씨	21.97%	10,566,637	-0.33%	특별관계자 해소	일반	2026-04-01
디티씨	22.30%	10,726,637	+1.00%	장내매수 및 특별관계자 추가	일반	2025-01-10
루멘스홀딩스	0.00%	0	-20.35%	주식양수도계약 이행에 따른 주식양도, 특별관계해소, 대표보고자변경으로 인한 변동	일반	2025-01-09
디티씨	21.30%	10,246,637	+21.30%	장내매수 및 장외매매(주식양수도) 계약 체결	일반	2024-11-22
루멘스홀딩스	20.35%	9,786,637	0.00%	주식 양수도 계약 체결	일반	2024-11-21
루멘스홀딩스	20.35%	9,786,637	+1.58%	장내매수 특별관계자 보유주식 등의 수 및 보유비율 변동	일반	2024-05-28

Major shareholders

Major shareholders (7 people)

Based on 2025 Business report

Name	Shares owned	Ownership	Relationship
디티씨	10,566,637	21.97%	-
와이앤에스	2,083,574	4.33%	-
이완용	1,045,000	2.17%	-
임현찬	959,768	2.00%	-
윤정미	958,190	1.99%	-
배원희	755,194	1.57%	-
오디텍	562,408	1.17%	-

Auditors

Analysis date 2026.08.15 02:04

Auditor	Type	Term start	Term end	Tenure	D-day
정기옥	Auditor	2016.04.01	-	10 years	-
이성규	Auditor	2025.01.03	2028.01.02	1 years	D-424

Executives

Name	Position	Category	Age	Term end
성재생	독립이사	독립이사	Age 78	D-876
박윤민	회장	Inside director	Age 64	D-424
이성규	감사	감사	Age 61	D-424
윤대한	대표이사	Inside director	Age 57	D-876

DART disclosures

Loading disclosures…

Activism & governance

Board and audit Importance 3 2026.09.02 15:00

루멘스, 임시주총서 사명 변경과 이사 선임안 처리

루멘스가 임시주주총회에서 정관 변경, 주식병합, 사내이사·사외이사 선임 안건을 처리하고 사명을 루멘스바이오스로 변경했다. 감사 후보 사퇴로 감사 선임 안건은 폐기됐다.

Shareholder perspective 주식병합과 정관·이사 구성 변경은 상장사의 자본구조와 이사회 운영에 영향을 주는 주주총회 의결 사항이다.

Control disputes Importance 3 2026.08.21 08:30

루멘스, 경영권 프리미엄을 반영한 주주총회 절차 진행

루멘스는 임시주주총회 소집과 의결권 대리행사 권유 관련 공시를 냈다. 기사에서는 루멘스 주식 거래 계약의 종가 대비 경영권 프리미엄이 거론됐다.

Shareholder perspective 상장사 루멘스의 임시주주총회와 경영권 거래가 연결된 사건으로, 주주 의결권과 지배권 변동에 영향을 줄 수 있다. 기사에 명시된 범위 밖의 거래 세부사항은 확인하지 않았다.

Ownership changes Importance 4 2026.08.18 09:30

루멘스, 최대주주 변경 수반 주식양수도 계약 체결

루멘스는 최대주주 변경을 수반하는 주식양수도 계약을 체결했다. 디티씨와 넥스턴앤롤코리아의 보유 지분은 각각 21.97%로 보고됐다.

Shareholder perspective 최대주주 변경을 수반한 지분 거래는 상장사의 경영권과 지배구조 변화를 직접 일으키는 사건이다.

루멘스바이오스 KOSDAQ

Upcoming shareholder meeting Collapse Upcoming shareholder meeting

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Consolidated

Separate

Legacy summary & estimates

Property holdings Collapse Property holdings

Ownership structure Collapse Ownership structure

Corporate shareholders Collapse Corporate shareholders

Business report analysis Collapse Business report analysis

사업 개요

주요 매출원

원가 구조 / 비용 특성

자회사

차입 구조

Articles of incorporation analysis Collapse Articles of incorporation analysis

주주친화

주주비친화

기타 주목 조항

Board of directors

Auditors

Shareholder meetings and dividends

Third-party allotment limit by board resolution alone

Compensation basis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Major shareholders Collapse Major shareholders

Major shareholders (7 people)

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures

Activism & governance Collapse Activism & governance

루멘스, 임시주총서 사명 변경과 이사 선임안 처리

루멘스, 경영권 프리미엄을 반영한 주주총회 절차 진행

루멘스, 최대주주 변경 수반 주식양수도 계약 체결

Upcoming shareholder meeting

Meeting voting results

Financial indicators

Share price history

Shareholder distribution

Annual earnings Trend

Financial statements

Property holdings

Ownership structure

Corporate shareholders

Business report analysis

Articles of incorporation analysis

Executive compensation

Controlling shareholders

Holders of 5% or more

Major shareholders

Auditors

Executives

DART disclosures

Activism & governance